 | | PRD_002159 | | Name: | N-(4-methoxy-4-oxobutanoyl)-L-alanyl-L-alanyl-N-[(2S)-4-chloro-3-oxo-1-phenylbutan-2-yl]-L-prolinamide | | Formula: | C26 H35 Cl N4 O7 | | Definition date: | 2015-05-06 | | Last modified: | 2015-05-06 |
|
 | | PRD_002148 | | Name: | 2-methyl-L-alanyl-N-[(3R,4S,5S)-3-methoxy-1-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-{[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide | | Formula: | C39 H62 N6 O6 S | | Definition date: | 2015-03-25 | | Last modified: | 2023-11-03 |
|
 | | PRD_002151 | | Name: | 2-methyl-L-alanyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S)-1-carboxy-2-phenylethyl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide | | Formula: | C37 H61 N5 O8 | | Definition date: | 2015-03-25 | | Last modified: | 2023-11-03 |
|
 | | PRD_002153 | | Name: | 2-methyl-L-prolyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S)-1-carboxy-2-phenylethyl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide | | Formula: | C39 H63 N5 O8 | | Definition date: | 2015-03-25 | | Last modified: | 2023-11-03 |
|
 | | PRD_002154 | | Name: | N,2-dimethyl-L-alanyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S)-1-carboxy-2-phenylethyl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide | | Formula: | C38 H63 N5 O8 | | Definition date: | 2015-03-25 | | Last modified: | 2023-11-03 |
|
 | | PRD_002147 | | Name: | N-{(2R,4S,5S)-2-benzyl-5-[(tert-butoxycarbonyl)amino]-4-hydroxy-6-phenylhexanoyl}-L-leucyl-L-phenylalaninamide | | Formula: | C39 H52 N4 O6 | | Definition date: | 2015-03-09 | | Last modified: | 2015-03-16 |
|
 | | PRD_001233 | | Name: | cyclic-tris-phenylselenazole | | Formula: | C36 H30 N6 O3 Se3 | | Definition date: | 2015-03-04 | | Last modified: | 2023-11-03 |
|
 | | PRD_001234 | | Name: | cyclic-tris-leucylselenazole | | Formula: | C27 H36 N6 O3 Se3 | | Definition date: | 2015-03-04 | | Last modified: | 2023-11-03 |
|
 | | PRD_001235 | | Name: | cyclic-tris-valinylselenazole | | Formula: | C24 H30 N6 O3 Se3 | | Definition date: | 2015-03-04 | | Last modified: | 2023-11-03 |
|
 | | PRD_001236 | | Name: | cyclic-tris-alanylselenazole | | Formula: | C18 H18 N6 O3 Se3 | | Definition date: | 2015-03-04 | | Last modified: | 2023-11-03 |
|
 | | PRD_002132 | | Name: | (10S,13S,16S,19S)-16-benzyl-12-(N-methyl-L-alanyl-L-valyl)-3,14,17-trioxo-2,7,8,9,12,15,18-heptaazatetracyclo[19.2.2.1~6,9~.1~10,13~]heptacosa-1(23),6(27),7,21,24-pentaene-19-carboxylic acid | | Formula: | C37 H47 N9 O7 | | Definition date: | 2015-03-04 | | Last modified: | 2023-11-03 |
|
 | | PRD_002133 | | Name: | (17S,20S,23S,29S)-20-benzyl-29-{[(2S)-2-(methylamino)propanoyl]amino}-19,22,28-trioxo-2,11-dioxa-5,6,7,18,21,27-hexaazapentacyclo[29.2.2.2~12,15~.1~4,7~.0~23,27~]octatriaconta-1(33),4(38),5,12,14,31,34,36-octaene-17-carboxylic acid (non-preferred name) | | Formula: | C42 H50 N8 O8 | | Definition date: | 2015-03-04 | | Last modified: | 2015-03-04 |
|
 | | PRD_002139 | | Formula: | C51 H80 N7 O16 P S2 | | Definition date: | 2015-02-11 | | Last modified: | 2023-11-03 |
|
 | | PRD_001243 | | Name: | N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-[(2R,3S,4S)-1,3-dihydroxy-2,6-dimethylheptan-4-yl]-L-phenylalaninamide | | Formula: | C40 H61 N5 O7 | | Definition date: | 2015-02-04 | | Last modified: | 2023-11-03 |
|
 | | PRD_001256 | | Name: | bifunctional peptide | | Formula: | C39 H43 N5 O5 | | Definition date: | 2015-01-14 | | Last modified: | 2015-01-14 |
|
 | | PRD_001258 | | Name: | N-[4-({[(6S)-2-amino-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-gamma-glutamyl-L-gamma-glutamyl-L-glutamic acid | | Formula: | C29 H37 N9 O12 | | Definition date: | 2015-01-14 | | Last modified: | 2017-09-14 |
|
 | | PRD_001140 | | Name: | N-(4-fluorobenzoyl)-L-gamma-glutamyl-5-{[(S)-{[(1S)-1,3-dicarboxypropyl]amino}(hydroxy)phosphoryl]oxy}-L-norvaline | | Formula: | C22 H29 F N3 O13 P | | Definition date: | 2014-12-31 | | Last modified: | 2017-09-14 |
|
 | | PRD_001172 | | Name: | nosiheptide bound form | | Formula: | C51 H53 N13 O12 S6 | | Definition date: | 2014-12-10 | | Last modified: | 2014-12-10 |
|
 | | PRD_001255 | | Name: | Promothiocin A | | Formula: | C36 H47 N11 O8 S2 | | Definition date: | 2014-12-10 | | Last modified: | 2023-11-03 |
|
 | | PRD_001208 | | Name: | Stapled peptide (ACE)NWFNITN(DIV)LW(MK8)I(LYV)KKK | | Formula: | C106 H165 N27 O28 P | | Description: | MODIFIED FRAGMENT OF HIV GLYCOPROTEIN (GP41) | | Definition date: | 2014-12-03 | | Last modified: | 2014-12-03 |
|
 | | PRD_001209 | | Name: | Stapled peptide (ACE)NWFNITN(DIV)LW(MK8)IKKKK | | Formula: | C103 H161 N25 O22 | | Description: | MODIFIED FRAGMENT OF HIV GLYCOPROTEIN (GP41) | | Definition date: | 2014-12-03 | | Last modified: | 2014-12-03 |
|
 | | PRD_002118 | | Name: | N-[(4Z)-6-oxo-6-phenylhex-4-enoyl]-3-(8-phenyloctyl)-L-histidyl-L-seryl-O-phosphono-L-threoninamide | | Formula: | C39 H53 N6 O10 P | | Definition date: | 2014-12-03 | | Last modified: | 2014-12-03 |
|
 | | PRD_002126 | | Name: | N-[4-(benzoylamino)butanoyl]-3-(8-phenyloctyl)-L-histidyl-L-seryl-O-phosphono-L-allothreoninamide | | Formula: | C38 H54 N7 O10 P | | Definition date: | 2014-12-03 | | Last modified: | 2023-11-03 |
|
 | | PRD_002127 | | Name: | N-[4-(hydroxymethyl)benzoyl]-beta-alanyl-3-(8-phenyloctyl)-L-histidyl-L-seryl-O-phosphono-L-threoninamide | | Formula: | C38 H54 N7 O11 P | | Definition date: | 2014-12-03 | | Last modified: | 2020-06-27 |
|
 | | PRD_001254 | | Name: | PL-2 | | Formula: | C29 H45 N6 O9 P | | Definition date: | 2014-11-19 | | Last modified: | 2014-11-19 |
|
